title: Adenovirus-mediated shRNA interference against porcine circovirus type 2 replication both in vitro and in vivo.
abstract: Porcine circovirus type 2 (PCV2) is the primary causative agent of an emerging swine disease, postweaning multisystemic wasting syndrome (PMWS), which is responsible for the heavy economic losses in stockbreeding. There are no specific antiviral drugs for treatment of the virus infection. We have now constructed two recombinant adenoviruses expressing short-hairpin RNAs (shRNAs) directed against either ORF1 (rAdS1) or ORF2 (rAdS2) of PCV2 and measured the inhibition of PCV2 replication. The results showed that delivery of these shRNAs by recombinant adenovirus into PK15 cells could induce a significant inhibition of viral RNA and DNA replication and protein synthesis level in cells subsequently infected with PCV2. The antiviral effect was dose-dependent and could sustain at least for 120h and the inhibition of virus replication could be significantly strengthened by combination of rAdS1 with rAdS2. Mice injected with shRNA before PCV2 infection showed substantial and low level of PCV2 DNA replication in the spleen during the period of 21-28 days post-PCV2 infection. These results indicated that shRNAs generated by adenovirus could sufficiently and continuously inhibit PCV2 infection in vitro as well as in vivo. The adenovirus based shRNA targeting ORF1 and ORF2 of PCV2 might be a new potential alternative strategy for controlling PCV2 infection.
authors.affiliation: Key Laboratory of Animal Diseases Diagnostic and Immunology, College of Veterinary Medicine, Nanjing Agricultural University, Ministry of Agriculture, Nanjing 210095, China.
authors.forename: Zhixin
authors.initials: Z
authors.lastname: Feng
authors.forename: Ping
authors.initials: P
authors.lastname: Jiang
authors.forename: Xianwei
authors.initials: X
authors.lastname: Wang
authors.forename: Yufeng
authors.initials: Y
authors.lastname: Li
authors.forename: Wenming
authors.initials: W
authors.lastname: Jiang
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D018173:Circoviridae Infections / Q000517:prevention & control; D017925:Circovirus / Q000187:drug effects* / Q000254:growth & development*; D004279:DNA, Viral / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D034741:RNA, Small Interfering / Q000096:biosynthesis / Q000235:genetics / Q000494:pharmacology*; D012367:RNA, Viral / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D013154:Spleen / Q000821:virology; D014764:Viral Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D014779:Virus Replication / Q000187:drug effects* / Q000235:genetics
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D034741:RNA, Small Interfering; D012367:RNA, Viral; D014764:Viral Proteins